Mathew S. Maurer

NewYork–Presbyterian Hospital — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

69h-index22.6kcitations529works11.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Amyloidosis: Diagnosis, Treatment, Outcomes(310), Parathyroid Disorders and Treatments(164), Cardiovascular Function and Risk Factors(80), Heart Failure Treatment and Management(48), Eosinophilic Disorders and Syndromes(48)

Publications528 total

Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study
Journal of the American Heart Association·2025· 1 citedOpen Access
Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy
Journal of the American Heart Association·2025Open Access
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Circulation·2025· 2 citedOpen Access
Abstract 4342359: Comprehensive Plasma Proteomics Profiling Identifies Circulating Biomarkers to Predict Both All-cause Mortality and Disease Progression in Patients with Transthyretin Amyloid Cardiomyopathy
Circulation·2025
Abstract 4342247: Machine learning of echocardiographic left ventricular myocardial radiomics for identification of transthyretin amyloid cardiomyopathy
Circulation·2025
Abstract 4352833: Fully Automated vs. Human Echocardiogram Interpretation in Transthyretin Amyloid Cardiomyopathy: The SCAN-MP Study
Circulation·2025
Abstract 4368185: Serum Transthyretin Levels at Day 28 are Associated with Cardiovascular Outcomes: Insights From the ATTRibute-CM Study
Circulation·2025
Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy
Blood·2025
Abstract 4350904: Comprehensive Plasma Transcriptomics Profiling Identifies a Small Set of Circulating MicroRNA Biomarkers to Distinguish Hypertrophic Cardiomyopathy from Other Cardiomyopathies with Left Ventricular Hypertrophy
Circulation·2025
Clinical Implications of the P.V142I TTR Variant
JACC Heart Failure·2025
Endothelial Cell‐Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy
Journal of the American Heart Association·2025Open Access
A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis
Amyloid·2025
The FLC Ratio Reframed
JACC CardioOncology·2025Open Access
Forging a New Path: Evolving Training Experiences and Challenges in Cardiac Amyloidosis Fellowships
Journal of Cardiac Failure - Intersections·2025Open Access
Developing therapeutics for rare cardiovascular diseases
American Heart Journal·2025Open Access
Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy
JACC Advances·2025Open Access
A cautionary case series: tafamidis mistreatment following erroneous diagnosis of transthyretin cardiac amyloidosis
Amyloid·2025
Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure
JAMA Cardiology·2025· 4 citedOpen Access
Diagnostic pathways, cardiac manifestations, and outcomes in light chain amyloidosis: a plain language summary
Future Cardiology·2025Open Access
Concurrent TTR and AL Amyloidosis
JACC Case Reports·2025· 1 citedOpen Access
page 1 of 27Next →

Frequent Co-authors

Martha Grogan(9), Daniel Burkhoff(9), Adam Castaño(8), Sabahat Bokhari(7), Thibaud Damy(7), Daniel P. Judge(6), José Nativi-Nicolau(5), Arnt V. Kristen(5), Joshua R. Vest(5), Martin B. Leon(4), Mazen Hanna(4), Susheel Kodali(4), Brian Drachman(4), Claudio Rapezzi(4), Giampaolo Merlini(4), Teresa Coelho(4), Ole B. Suhr(4), John L. Berk(4), Pushkal Garg(4), Julian D. Gillmore(4)